$LLY
AI AnalysisGenerated on May 11, 2026
AI Score
Hold$LLY
Eli Lilly and Company
$LLYNYSEHealthcareMega-Cap
Eli Lilly discovers, develops, and markets pharmaceutical products, with leading positions in diabetes (Mounjaro), obesity (Zepbound), and oncology.
Market Cap
$720.0B
Revenue (TTM)
$41.3B
+32.0%
Net Income (TTM)
$9.4B
+68.0%
EPS (TTM)
$10.35
P/E Ratio
72.0
Dividend Yield
0.7%
52-Week Range
$600-$972
Beta
0.42
Dimension Scores
Fundamental
72Technical
62Sentiment
78Risk / Reward
60Momentum
82Financial Health
Profitability
77strong
Growth
85strong
Liquidity
68strong
Solvency
74strong
Efficiency
70strong
Valuation, technical analysis, investment thesis, risk assessment and more for $LLY
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.